Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.45 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glucosamine SCHEMBL15596846 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Glucosamine SCHEMBL17038892 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Glucosamine SCHEMBL22748633 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Glucosamine SCHEMBL19441236 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Glucosamine SCHEMBL24336697 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Glucosamine SCHEMBL12598845 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Glucosamine SCHEMBL25225908 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Glucosamine SCHEMBL21240813 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Glucosamine SCHEMBL22748715 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Glucosamine SCHEMBL22137006 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250121067-A1 | WATER-SOLUBLE CANNABINOID PRODRUGS COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | TRAIT BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | claimed |
| EP-4531836-A1 | WATER-SOLUBLE CANNABINOID PRODRUGS COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | Trait Biosciences, Inc. (US) | 2025-04-09 | — | — | EP | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| US-11884961-B2 | DNA-glycan conjugates and methods of use | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-01-30 | — | — | US | claimed |
| WO-2023235386-A1 | WATER-SOLUBLE CANNABINOID PRODRUGS COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | TRAIT BIOSCIENCES, INC. (US) | 2023-12-07 | — | — | WO | claimed |
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | INBIOSE N V (BE) | 2026-05-21 | — | — | US | disclosed |
| EP-4694910-A1 | COMPOSITIONS AND USES THEREOF FOR TREATING DISEASES OR DISORDERS ASSOCIATED WITH GAS5 LNCRNA SIGNALING DYSFUNCTION | The University of South Florida (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4686760-A1 | SIALYLTRANSFERASES FOR THE SYNTHESIS OF SIALYLATED GLYCANS, GLYCOCONJUGATES AND GLYCOPROTEINS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-02-04 | — | — | EP | disclosed |
| US-20250361477-A1 | PRODUCTION OF AN OLIGOSACCHARIDE MIXTURE BY A CELL | INBIOSE NV (BE) | 2025-11-27 | — | — | US | disclosed |
| WO-2025245504-A1 | PRODUCTION OF FORMATE, GLYCOLATE, AND HYDROGEN FROM CARBOHYDRATES USING VIOLENE CATALYSTS | WATT POWER INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4608849-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | Inbiose N.V. (BE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4594530-A1 | NUCLEIC ACID SEQUENCING COMPONENTS INCLUDING A GLYCOLIPID BI-LAYER | Illumina, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2021160829-A1 | VIABLE BACTERIAL HOST CELL | INBIOSE N.V. (BE) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021160830-A1 | GLYCOMINIMIZED BACTERIAL HOST CELLS | INBIOSE N.V. (BE) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021074182-A1 | PRODUCTION OF BIOPRODUCT IN A HOST CELL | INBIOSE N.V. (BE) | 2021-04-22 | — | — | WO | disclosed |
| US-20210040470-A1 | AN ENZYME CONTAINING POLYMER, A SENSOR CONTAINING THE SAME, A MONITOR AND A MONITORING METHOD | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2021-02-11 | — | — | US | disclosed |
| CN-112272709-A | Enzyme-containing polymer, sensor, monitor and monitoring method comprising enzyme-containing polymer | 新加坡保健服务集团有限公司 | 2021-01-26 | — | — | CN | disclosed |
| WO-2019199233-A1 | AN ENZYME CONTAINING POLYMER, A SENSOR CONTAINING THE SAME, A MONITOR AND A MONITORING METHOD | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2019-10-17 | — | — | WO | disclosed |
| US-7462746-B2 | Amino polyols and amino sugars | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462746-B2 | Amino polyols and amino sugars | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2008-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250121067-A1 | WATER-SOLUBLE CANNABINOID PRODRUGS COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | CNR2, CNR1, BSG | LGALS1 2508/4885LGALS3 2302/4885LGALS9 2225/4885 |
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | GALNT3, NANS, ENGASE | LGALS1 38/4885LGALS3 13/4885LGALS9 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.